Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Entrada Therapeutics (Nasdaq: TRDA), a clinical-stage biopharmaceutical company focused on developing medicines for intracellular targets, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Dipal Doshi will deliver a presentation on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET).
The presentation will be accessible via live webcast on the company's Investor Relations website, with a replay available for 30 days following the event. Entrada's mission centers on transforming patient lives by creating innovative treatments that can reach previously inaccessible intracellular targets.
Entrada Therapeutics (Nasdaq: TRDA), un'azienda biofarmaceutica in fase clinica focalizzata nello sviluppo di farmaci per target intracellulari, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale sulla Sanità J.P. Morgan. Il CEO Dipal Doshi presenterà il suo intervento mercoledì 15 gennaio 2025, alle 11:15 ora del Pacifico (14:15 ora dell'Est).
La presentazione sarà accessibile tramite webcast dal vivo sul sito web delle Relazioni con gli Investitori della compagnia, con una registrazione disponibile per 30 giorni dopo l'evento. La missione di Entrada è trasformare la vita dei pazienti creando trattamenti innovativi che possano raggiungere target intracellulari precedentemente inaccessibili.
Entrada Therapeutics (Nasdaq: TRDA), una compañía biofarmacéutica en etapa clínica centrada en el desarrollo de medicamentos para objetivos intracelulares, ha anunciado su participación en la 43ª Conferencia Anual de Salud J.P. Morgan. El CEO Dipal Doshi dará una presentación el miércoles 15 de enero de 2025, a las 11:15 a.m. PT (2:15 p.m. ET).
La presentación será accesible a través de una transmisión en vivo en el sitio web de Relaciones con Inversionistas de la compañía, con una repetición disponible durante 30 días después del evento. La misión de Entrada se centra en transformar la vida de los pacientes creando tratamientos innovadores que puedan alcanzar objetivos intracelulares previamente inaccesibles.
Entrada Therapeutics (Nasdaq: TRDA), 세포 내 표적을 위한 약물을 개발하는 데 집중하는 임상 단계의 생명공학 회사는 제43회 연례 J.P. 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO Dipal Doshi는 2025년 1월 15일 수요일, 오전 11시 15분 PT (오후 2시 15분 ET)에 발표를 진행할 예정입니다.
발표는 회사의 투자자 관계 웹사이트에서 생중계로 이용 가능하며, 행사 후 30일 동안 다시 시청할 수 있습니다. Entrada의 사명은 이전에 접근할 수 없었던 세포 내 표적에 도달할 수 있는 혁신적인 치료법을 창출함으로써 환자의 삶을 변화시키는 것입니다.
Entrada Therapeutics (Nasdaq: TRDA), une entreprise biopharmaceutique en phase clinique axée sur le développement de médicaments pour des cibles intracellulaires, a annoncé sa participation à la 43e Conférence Annuelle sur la Santé J.P. Morgan. Le PDG Dipal Doshi fera une présentation le mercredi 15 janvier 2025, à 11h15 PT (14h15 ET).
La présentation sera accessible en direct sur le site des Relations Investisseurs de la société, avec un enregistrement disponible pendant 30 jours après l'événement. La mission d'Entrada est de transformer la vie des patients en créant des traitements innovants capables d'atteindre des cibles intracellulaires qui étaient auparavant inaccessibles.
Entrada Therapeutics (Nasdaq: TRDA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Medikamenten für intra-zelluläre Ziele konzentriert, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. CEO Dipal Doshi wird am Mittwoch, dem 15. Januar 2025, um 11:15 Uhr PT (14:15 Uhr ET) einen Vortrag halten.
Die Präsentation wird über einen Live-Webcast auf der Investor Relations-Website des Unternehmens zugänglich sein, und eine Wiederholung wird 30 Tage nach der Veranstaltung verfügbar sein. Die Mission von Entrada besteht darin, das Leben der Patienten zu transformieren, indem innovative Behandlungen geschaffen werden, die zuvor unzugängliche intra-zelluläre Ziele erreichen können.
- None.
- None.
BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET).
A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event.
About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The Company’s lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45 and 50 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
For more information about Entrada, please visit our website, www.entradatx.com, and follow us on LinkedIn.
Investor and Media Contact
Caileigh Dougherty
Head of Investor Relations & Corporate Communications
cdougherty@entradatx.com
FAQ
When is Entrada Therapeutics (TRDA) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors access Entrada Therapeutics' (TRDA) J.P. Morgan Healthcare Conference presentation?
What is Entrada Therapeutics' (TRDA) main focus in drug development?
How long will the replay of Entrada's (TRDA) J.P. Morgan Healthcare Conference presentation be available?
